We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ZBAO:NASDAQZhibao Technology Inc. Analysis

Data as of 2026-07-31 - not real-time

$0.17

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Zhibao Technology (ZBAO) is trading deep in the red at $0.1725, well below its DCF fair‑value estimate of $53.19, indicating a massive valuation gap. The 20‑day SMA (0.27) sits beneath the 50‑day (0.52) and 200‑day (0.80) averages, confirming a persistent bearish price trend. Momentum is mixed: RSI at 33 suggests the stock is oversold, while the MACD histogram has turned slightly positive, hinting at a tentative bounce. Volatility is extreme, with a 30‑day swing of over 255% and a historical max drawdown of –87%, underscoring the price’s erratic nature. Revenue growth of 40.7% and a new embedded‑insurance deployment targeting 20 million users provide a compelling growth narrative. However, operating cash flow remains strongly negative and the company carries a debt‑to‑equity ratio above 100%, raising solvency concerns. The recent Nasdaq deficiency letter adds regulatory uncertainty, while the expansion partnership with Tianfu Citizen’s Cloud offers a material upside catalyst. Liquidity is thin, with a market cap of roughly $5.9 million and modest trading volumes despite a recent uptick. In sum, the stock presents a classic high‑risk, high‑potential profile where valuation appears attractive but fundamentals and external risks are severe.
Given the confluence of deep discount, aggressive growth initiatives, and significant operational and compliance headwinds, investors should treat ZBAO as a speculative play. Short‑term price action may linger near the $0.15 support, but a breakthrough in cash‑flow generation or resolution of the Nasdaq notice could unlock upside. Conversely, continued earnings losses and tightening regulation could drive the stock toward its lower support, eroding the already limited upside.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price hovering near technical support at $0.15
  • RSI indicating oversold conditions
  • Nasdaq deficiency letter heightening compliance risk

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • 40%+ revenue growth and access to 20 million new users
  • DCF fair‑value suggesting massive upside
  • Potential resolution of Nasdaq compliance issues

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Sustained negative earnings and high debt load
  • Extreme price volatility and historical drawdown
  • Uncertain regulatory environment for Chinese InsurTech

Key Metrics & Analysis

Financial Health

Revenue Growth40.70%
Profit Margin-19.52%
ROE-99.67%
ROA-11.02%
Debt/Equity111.55
P/B Ratio1.9
Op. Cash Flow$-107109984
Free Cash Flow$52.5M
Industry P/E18.1

Technical Analysis

TrendBearish
RSI33.2
Support$0.15
Resistance$0.58
MA 20$0.27
MA 50$0.52
MA 200$0.80
MACDBullish
VolumeIncreasing
Fear & Greed Index90.91

Valuation

Fair Value$53.19
GradeUndervalued
TypeGrowth

Risk Assessment

Beta0.16
Volatility255.84%
Sector RiskHigh
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.